JLS Fund

Immunis is a private biotechnology company focused on creating innovative therapies to address immune decline associated with aging and various diseases. The company is developing a stem cell-derived treatment that utilizes human stem cells to generate specific populations of cells. These engineered cells are designed to secrete therapeutic factors that can help restore and modulate the immune system. By harnessing the potential of stem cells, Immunis aims to provide effective solutions for improving immune health and enhancing patient outcomes.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

Homecoming is a provider of patient engagement tools tailored for psychedelic therapy. The company has developed a digital companion application that supports patients throughout their healing process. This application promotes accountability and long-term change by offering personalized guides, tasks, and daily check-ins, all within a user-friendly platform. It also facilitates preparation and integration support, enabling healthcare professionals to effectively guide their patients. Homecoming's focus on enhancing the therapeutic experience aims to improve outcomes for individuals undergoing psychedelic therapy.

Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge of the mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend.

Psilera is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases and mental health disorders. The company focuses on creating a new class of neurological medicines, with its lead asset, PSIL-006, being a non-hallucinogenic psilocybin derivative aimed at treating frontotemporal dementia (FTD). Psilera's approach involves repurposing psychoactive natural products to develop next-generation therapies that enhance cognitive function and address mood and substance use disorders. Committed to scientific excellence, Psilera aims to transform the lives of individuals affected by these challenging conditions through its pioneering research and development efforts.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

WeSana Health is a life sciences company that provides advancement of psilocybin-based medicine. The company was founded in 2020 by Daniel Carcillo and is headquartered in Homer Glen, Illinois, United States.